DE602005021530D1 - Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate - Google Patents

Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate

Info

Publication number
DE602005021530D1
DE602005021530D1 DE602005021530T DE602005021530T DE602005021530D1 DE 602005021530 D1 DE602005021530 D1 DE 602005021530D1 DE 602005021530 T DE602005021530 T DE 602005021530T DE 602005021530 T DE602005021530 T DE 602005021530T DE 602005021530 D1 DE602005021530 D1 DE 602005021530D1
Authority
DE
Germany
Prior art keywords
dried formulation
cephalosporin derivatives
stabilized freeze
freeze
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021530T
Other languages
English (en)
Inventor
Markus Heubes
Wilhelm Scigalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Publication of DE602005021530D1 publication Critical patent/DE602005021530D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005021530T 2004-11-10 2005-11-10 Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate Active DE602005021530D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405690A EP1656930A1 (de) 2004-11-10 2004-11-10 Stabilisierte gefriergetrocknete Formulierung für Cephalosporinderivate
PCT/CH2005/000665 WO2006050631A1 (en) 2004-11-10 2005-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives

Publications (1)

Publication Number Publication Date
DE602005021530D1 true DE602005021530D1 (de) 2010-07-08

Family

ID=34932353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021530T Active DE602005021530D1 (de) 2004-11-10 2005-11-10 Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate

Country Status (24)

Country Link
US (2) US20080032962A1 (de)
EP (3) EP1656930A1 (de)
JP (1) JP2008519775A (de)
KR (1) KR20070084150A (de)
CN (1) CN101056623B (de)
AR (1) AR052233A1 (de)
AT (1) ATE468844T1 (de)
AU (1) AU2005304252B2 (de)
BR (1) BRPI0517305A (de)
CA (1) CA2585296A1 (de)
CY (1) CY1110731T1 (de)
DE (1) DE602005021530D1 (de)
DK (1) DK1809253T3 (de)
ES (1) ES2342833T3 (de)
HR (1) HRP20100364T1 (de)
MX (1) MX2007005677A (de)
MY (1) MY142648A (de)
PL (1) PL1809253T3 (de)
PT (1) PT1809253E (de)
RS (1) RS51380B (de)
SI (1) SI1809253T1 (de)
TW (1) TW200630118A (de)
WO (1) WO2006050631A1 (de)
ZA (1) ZA200703760B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
WO2008072535A1 (ja) 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
JP2011514902A (ja) * 2008-03-04 2011-05-12 エラン・ファルマ・インターナショナル・リミテッド 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画
EP2106788A1 (de) * 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
EP2236520A1 (de) * 2009-03-31 2010-10-06 Leukocare Ag Stabilisierungszusammensetzung für immobilisierte Biomoleküle
US20130089638A1 (en) 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
CN102727451B (zh) * 2012-07-03 2013-07-03 哈药集团制药总厂 一种含有头孢美唑钠的药物组合物
CN102716075B (zh) * 2012-07-03 2013-08-21 哈药集团制药总厂 一种含有头孢唑肟钠的药物组合物
CN103271877A (zh) * 2012-12-18 2013-09-04 张宏民 一种头孢西丁钠注射剂及其制备方法
MD4599C1 (ro) 2013-03-13 2019-06-30 Theravance Biopharma Antibiotics Ip, Llc Săruri de hidroclorură a unui compus antibiotic
CN110507619B (zh) * 2019-08-19 2021-12-03 湖北美林药业有限公司 注射用头孢哌酮钠及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
DE3801179A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
DE69004921T2 (de) * 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
JPH0459730A (ja) * 1990-06-26 1992-02-26 Dai Ichi Seiyaku Co Ltd セフェム系抗生物質含有凍結乾燥製剤
ATE231871T1 (de) * 1998-06-15 2003-02-15 Basilea Pharmaceutica Ag 3-(2-oxo-(1,3')bipyrrolidinyl-3-yliden-methyl)- cephemderivate
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
AU2003241675A1 (en) * 2002-06-21 2004-01-06 Shionogi And Co., Ltd. Medicinal cephem compound composition for injection

Also Published As

Publication number Publication date
EP2210592A2 (de) 2010-07-28
KR20070084150A (ko) 2007-08-24
HRP20100364T1 (hr) 2010-07-31
RS51380B (en) 2011-02-28
EP2210592A3 (de) 2011-12-14
ZA200703760B (en) 2008-06-25
EP1809253B1 (de) 2010-05-26
TW200630118A (en) 2006-09-01
CN101056623B (zh) 2011-04-06
AR052233A1 (es) 2007-03-07
PL1809253T3 (pl) 2010-10-29
PT1809253E (pt) 2010-09-03
MX2007005677A (es) 2007-07-20
EP1809253A1 (de) 2007-07-25
AU2005304252B2 (en) 2009-07-16
US20080032962A1 (en) 2008-02-07
CN101056623A (zh) 2007-10-17
SI1809253T1 (sl) 2010-09-30
WO2006050631A1 (en) 2006-05-18
EP1656930A1 (de) 2006-05-17
ATE468844T1 (de) 2010-06-15
MY142648A (en) 2010-12-15
JP2008519775A (ja) 2008-06-12
DK1809253T3 (da) 2010-07-12
CA2585296A1 (en) 2006-05-18
ES2342833T3 (es) 2010-07-15
US20100160278A1 (en) 2010-06-24
CY1110731T1 (el) 2015-06-10
AU2005304252A1 (en) 2006-05-18
BRPI0517305A (pt) 2008-10-07

Similar Documents

Publication Publication Date Title
DE602005021530D1 (de) Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
ITMI20050728A1 (it) Formulazione innovativa
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
FR20C1027I2 (fr) Derives de tiglien-3-one
DK1725553T3 (da) Tetrahydropyridoindolderivater
ATE540935T1 (de) Chinazolinderivate
ATE383361T1 (de) Pyrrazolopyrimidinderivate
ATE415400T1 (de) Pyrazolopyridinderivate
DE602005025484D1 (de) Breitband-Superlumineszenzdiode
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE512135T1 (de) Spiroindolinonderivate
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1868586T3 (da) Antiinflammatorisk formulering
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
ATE437856T1 (de) 5-aminoindol-derivate
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
DOP2006000261A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition